Long-Term Performance of Subcutaneous Implantable Defibrillators in Athletes: A Multicenter, Real-World Analysis of Sport Activities from the iSUSI Registry
Alessio Gasperetti,Marco Schiavone,Julia Vogler,Paolo Compagnucci,Mikael Laredo,Alexander Breitenstein,Simone Gulletta,Martin Martinek,Lukas Kaiser,Carlo Lavalle,Sean Gaine,Luca Santini,Antonio Dello Russo,Pietro Palmisano,Giovanni Rovaris,Antonio Curnis,Nicoletta Ventrella,Jürgen Kuschyk,Mauro Biffi,Roland Tilz,Luigi Di Biase,Claudio Tondo,Giovanni B Forleo,i-SUSI investigators
DOI: https://doi.org/10.1016/j.hrthm.2024.09.039
IF: 6.779
2024-09-20
Heart Rhythm
Abstract:Background: No data regarding subcutaneous-implantable cardioverter defibrillator (S-ICD) technology in patients actively engaging in sports activities are available. Objective: This study aims to compare S-ICD performance between athletes and nonathletes. Methods: The primary outcome of the study was the comparison of overall device-related complications between athletes and nonathletes. Appropriate shocks, inappropriate shocks, and individual device-related complications were secondary outcomes. Results: A total of 1493 patients were extracted from the International Subcutaneous Implantable Cardioverter Defibrillator Registry (iSUSI) registry, of whom 152 (10.2%) were athletes, mostly engaging in dynamic sports (54.2%). Brugada syndrome, myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC) were more common in athletes (11.2% vs 3.3%, P < .001; 19.1% vs 9.0%, P < .001; 8.6% vs 2.8%, P < .001, respectively). During a median follow-up time of 25.5 (12.0-41.2) months, athletes were more likely to experience appropriate shocks (yearly rate: 7.2 [4.9-10.7] % vs 4.3 [3.6-5.1] %, P = .028), occurring more frequently during exercise (3.9% vs 0.6%, P < .001). This finding lost significance when adjusting for confounders (adjusted hazard ratio [aHR] 1.440 [0.909-2.281], P = .120). No differences were found in overall device-related complications (yearly rate: 3.3% vs 3.4%, P = .448) and inappropriate shocks (yearly rate: 5.3% vs 3.7%, P = 0.111). Myopotential oversensing (4.0% vs 1.3%, P = .011) was more common in athletes, as were lead infections (3.3% vs 0.9%, P =.008), with the latter clustering in the early postimplantation period. Conclusion: The S-ICD is a valid therapeutic option for preventing sudden cardiac death in athletes. Sports practice was not associated with an increased risk of complications or inappropriate shocks, although athletes are exposed to a higher risk of S-ICD infections in the early postoperative period.